Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cezary Cybulski, Jan Lubiński, Pomorski Uniwersytet Medyczny W SzczeciniefiledCriticalCezary Cybulski
Priority to PL401271ApriorityCriticalpatent/PL236986B1/en
Publication of PL401271A1publicationCriticalpatent/PL401271A1/en
Publication of PL236986B1publicationCriticalpatent/PL236986B1/en
208000037265diseases, disorders, signs and symptomsDiseases0.000abstract1
239000003550markerSubstances0.000abstract1
Landscapes
Measuring Or Testing Involving Enzymes Or Micro-Organisms
(AREA)
Abstract
Wynalazek ujawnia sposoby i produkty znajdujące zastosowanie w diagnozowaniu genetycznej predyspozycji do chorób u ludzi i polega na ocenie czy w materiale biologicznym badanej osoby występuje specyficzna zmiana konstytucyjna w genie NBS1. Wynalazek obejmuje nową metodę diagnostyczną wykrywającą predyspozycję do agresywnego raka prostaty o złym rokowaniu oraz sposób i zestaw diagnostyczny dotyczący opracowania nowego markera złego rokowania dla raka stercza.The invention discloses methods and products used in the diagnosis of genetic predisposition to human diseases and consists in assessing whether a specific constitutional change in the NBS1 gene occurs in the biological material of the examined person. The invention includes a new diagnostic method that detects a predisposition to aggressive prostate cancer with poor prognosis, as well as a diagnostic method and kit for developing a new marker of poor prognosis for prostate cancer.
PL401271A2012-10-172012-10-17Method and kit for the detection of aggressive prostate cancer with poor prognosis
PL236986B1
(en)
method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual
“ccr5 antagonist, method for determining whether a human subject having prostate cancer is suffering from or at risk of developing metastasis, for identifying a candidate compound, for producing primary epithelial cells in vitro, for diagnosing prostate cancer, for selecting a treatment for an individual having a prostate cancer/tumor, cell line, and animal model”
Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease